Atherosclerosis
Sleep irregularity increases CVD risk
BLOG: New diabetes guidelines
As an optometrist interested in the evolution of my profession to include more primary health care, I have my Healio email subscriptions and alerts set to receive the Primary Care News Wire. Although I often just skim these articles, I sometimes find an item of interest that has implications for optometry. Such was the case last month when I read, “New diabetes guideline reflects change in glucose therapy considerations.” Published online on Jan. 22, 2020, this article will affect my doctoring of patients with diabetes as well as those at risk for developing the disease.
Brown fat may hold key to treatment of cardiometabolic disorders
Not all fat is bad. In fact, some fat can be very good — even body fat, according to Aaron M. Cypess, MD, PhD, MMSc, acting chief of the translational physiology section of the diabetes, endocrinology and obesity branch of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. Evidence from the past decade has pointed toward benefit from brown fat, and researchers are exploring its potential for treating obesity, diabetes and other cardiometabolic disorders.
Type of estrogen therapy influences heart fat deposition among postmenopausal women
Among healthy, postmenopausal women, hormone therapy with oral conjugated equine estrogens — compared with transdermal estradiol or no hormone therapy — may slow the adverse effects of heart fat accumulation on carotid intima-media thickness , according to an analysis of the KEEPS study published in Menopause.
New use for an old drug: The potential of colchicine in CVD
Obesity causally linked to aortic valve stenosis, replacement
Vascular calcification present in mummies despite marine diet
Despite presumably living a physically active lifestyle and eating a diet rich in omega-3 fatty acids, three of four Inuit adolescent or young adult mummies who lived approximately 500 years ago had vascular calcification, according to a new case series from the Horus Study Group published in JAMA Network Open.
Diabetes, atherosclerosis increase cancer risks
Icosapent ethyl may act on plaque
A potential target for improving residual lipid-related risk for atherosclerotic CVD is reduction in triglyceride levels. Studies have shown eicosapentaenoic acid is effective in lowering triglyceride levels and reducing the risk for ischemic events in patients with elevated triglyceride levels already taking statin therapy.